Aadi Bioscience (NASDAQ:AADI) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Aadi Bioscience (NASDAQ:AADI) from a sell rating to a hold rating in a research report report published on Tuesday, Zacks.com reports. They currently have $27.00 price target on the stock.

According to Zacks, “Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES. “

A number of other equities analysts also recently commented on AADI. Cowen began coverage on Aadi Bioscience in a research report on Friday, October 1st. They set an outperform rating for the company. Jefferies Financial Group initiated coverage on Aadi Bioscience in a research report on Tuesday. They set a buy rating and a $45.00 price objective for the company. HC Wainwright boosted their target price on Aadi Bioscience from $47.00 to $49.00 and gave the stock a buy rating in a research note on Wednesday, November 24th. Finally, LADENBURG THALM/SH SH initiated coverage on Aadi Bioscience in a research note on Tuesday, September 14th. They set a buy rating and a $51.00 target price for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Aadi Bioscience has a consensus rating of Buy and a consensus price target of $43.40.

NASDAQ AADI opened at $24.51 on Tuesday. The company has a market cap of $512.11 million, a P/E ratio of -1.83 and a beta of 1.51. The stock has a 50-day moving average of $23.64 and a two-hundred day moving average of $26.40. Aadi Bioscience has a 1-year low of $14.31 and a 1-year high of $49.80.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings data on Wednesday, November 10th. The company reported ($1.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.78). On average, sell-side analysts anticipate that Aadi Bioscience will post 4.78 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. US Bancorp DE purchased a new stake in shares of Aadi Bioscience during the third quarter worth approximately $98,000. Parallel Advisors LLC purchased a new stake in shares of Aadi Bioscience during the third quarter worth approximately $188,000. BlackRock Inc. purchased a new stake in shares of Aadi Bioscience during the third quarter worth approximately $478,000. XTX Topco Ltd purchased a new stake in shares of Aadi Bioscience during the second quarter worth approximately $29,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Aadi Bioscience during the third quarter worth approximately $825,000. Institutional investors own 64.48% of the company’s stock.

About Aadi Bioscience

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in October, 2011 and is headquartered in Los Angeles, CA.

Featured Article: Non-Fungible Token (NFT) Explained

Get a free copy of the Zacks research report on Aadi Bioscience (AADI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aadi Bioscience (NASDAQ:AADI)

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.